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Purpose: To describe the distribution of diagnostic procedures, rates of complications, and
total cost of biopsies for patients with lung cancer.
Patients and Methods: Observational study using data from IBM Marketscan® Databases
for continuously insured adult patients with a primary lung cancer diagnosis and treatment
between July 2013 and June 2017. Costs of lung cancer diagnosis covered 6 months prior to
index biopsy through treatment. Costs of chest CT scans, biopsy, and post-procedural
complications were estimated from total payments. Costs of biopsies incidental to inpatient
admissions were estimated by comparable outpatient biopsies.
Results: The database included 22,870 patients who had a total of 37,160 biopsies, of which
16,009 (43.1%) were percutaneous, 14,997 (40.4%) bronchoscopic, 4072 (11.0%) surgical
and 2082 (5.6%) mediastinoscopic. Multiple biopsies were performed on 41.9% of patients.
The most common complications among patients receiving only one type of biopsy were
pneumothorax (1304 patients, 8.4%), bleeding (744 patients, 4.8%) and intubation (400
patients, 2.6%). However, most complications did not require interventions that would add
to costs. Median total costs were highest for inpatient surgical biopsies ($29,988) and lowest
for outpatient percutaneous biopsies ($1028). Repeat biopsies of the same type increased
costs by 40–80%. Complications account for 13% of total costs.
Conclusion: Costs of biopsies to confirm lung cancer diagnosis vary substantially by type
of biopsy and setting. Multiple biopsies, inpatient procedures and complications result in
higher costs.
Keywords: cancer, diagnosis, economics, frequency

Introduction

Correspondence: Dean G Smith
LSU Health Sciences Center – New
Orleans, School of Public Health, 2020
Gravier St., New Orleans, LA, 70112,
USA
Email dgsmith@lsuhsc.edu

Lung cancer is the leading cause of cancer-related deaths in both the United States
and the world, causing more deaths than colorectal, breast, and prostate cancers
combined. An estimated 154,050 Americans died of lung cancer in 2018, account
ing for about 26% of all cancer deaths in the United States.1 The overall 5-year
survival rate for patients with lung cancer is poor relative to the other major cancers
(18.6%, vs 64.5% colorectal, 89.7% breast and 98.2% prostate). Survival rates vary
from 53.6% for patients with localized disease, to 29.7% for patients with region
ally invasive disease (local lymph nodal extension), and 4.7% for people with
metastatic disease.2
Due to the lack of symptoms in the early stages of disease, most lung cancers
(84%) are diagnosed late with the regional or distant extension of the disease,
limiting treatment options and impacting survival.2 A variety of imaging technol
ogies are used to identify suspicious lesions, but the discriminatory capability of
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existing imaging technologies for diagnosis does not exist.
Early detection of lung cancer offers the potential to mod
ify the entire landscape of health services offered, perhaps
at substantially lower costs to patients and health plans.
Tissue biopsy procedures play an essential role in the
clinical pathway for the diagnosis of lung cancer.
Guidelines, including those of the American College of
Chest Physicians and National Comprehensive Cancer
Network, are available to assess options that are best suited
to different clinical scenarios.3,4 With the advent of new
clinical assays to test for both germline and somatic altera
tions that are prognostic and/or predictive of disease out
come, toxicity or treatment, biopsy yield and specimen
quality are critical to determine whether patients are candi
dates for specific therapies.5 Inconclusive diagnostic proce
dures increase the need for repeat biopsy, extend the time to
treatment, add cost burden and undue psychological stress
for patients and their families.
The objective of this paper is to describe the distribu
tion of diagnostic procedures, rates of complications, and
total cost of procedures related to lung cancer diagnosis
using data from a US administrative claims database.

Patients and Methods
Database
This observational study utilized data from both the IBM
Marketscan® Commercial Claims and Encounters and
Medicare Supplemental Databases.6 The Marketscan®
Databases are constructed from privately insured, paid,
medical and prescription drug claims contributed by
employers and health plans who have business relation
ships with IBM Watson Health. Collectively, the data are
incorporated from approximately 350 payers, including
commercial insurance companies, Blue Cross and Blue
Shield plans, and third-party administrators and include
approximately 62 million covered lives. Each contributor’s
database is constructed by collecting raw data from the
participating payer(s). These raw data are service-level
adjudicated paid claims and capitated encounters contain
ing both inpatient and outpatient services. As the database
is fully de-identified and compliant with HIPAA regula
tions this study was exempted from Institutional Review
Board approval.6

Study Population
The target population included patients aged 18 years and
older who had one primary lung cancer diagnosis between

192

submit your manuscript | www.dovepress.com

DovePress

July 1, 2013 and June 30, 2017 and had treatment after the
diagnosis of lung cancer reported on medical claims. The
diagnosis of lung cancer was based on the use of identified
codes from the International Classification of Diseases,
Ninth Revision (ICD-9-CM 162.x) and the International
Classification of Diseases, Tenth Revision (ICD-10 C33,
C34.xx) as both systems were used during the study per
iod. Treatment was defined by identifying Current
Procedural Terminology (CPT) and/or ICD-9-CM or
ICD-10-CM procedure codes for surgery, ablation, radia
tion therapy or chemotherapy, and the National Drug Code
(NDC) for therapeutic agents used in the treatment of lung
cancer in relation to a procedure. Patients without evi
dence of health plan enrollment 6 months prior to and
after their diagnosis and those who did not receive any
lung cancer treatment after diagnosis were excluded from
the focused study population (Figure 1).

Study Variables
We extracted the following information from the IBM
MarketScan® database: date of diagnosis, type and number
of procedures, cancer history, comorbidity, age, gender,
and type of insurance plan. Comorbidity was calculated
using Charlson comorbidity index score.7,8 Having only
administrative data, other characteristics such as disease
stage are unavailable. Procedures were stratified into four
categories: CT-guided percutaneous biopsy, bronchoscopy,
surgical biopsy, and mediastinoscopy. Chest CT scans
were identified with CPT codes (71250, 71260, or
71270). Biopsy-related complications captured were pneu
mothorax, prolonged air leak, hemorrhage, post-treatment
change to intubated/mechanical ventilation, mediastinitis,
pneumonia, empyema and abscess of lung. ICD-9-CM or
ICD-10-CM diagnosis codes were used to identify quali
fying post-procedural complications (Supplement
Information). Complications must have occurred within
a day immediately following the biopsy procedure to be
considered biopsy-related, except for prolonged air leak
and abscess of the lung. For these complications, the time
interval was 5 days after the biopsy date. To derive com
plications and costs associated with each particular type of
biopsy, we excluded patients who received more than one
type of biopsy from the analysis. In addition, thoracotomy;
with diagnostic wedge resection followed by anatomic
lung resection (CPT code 32668) and thoracoscopy, surgi
cal; with diagnostic wedge resection followed by anatomic
lung resection (CPT code 32507) were excluded from the
complications analysis, since we are unable to determine if
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Patients with primary lung cancer
diagnosis and
treatment identified, 2013-2017
N=73,732
Patient diagnosed before July 1,
2013 or after June 30, 2017
N=24,789
Primary lung cancer diagnosis and
treatment
July 1, 2013 and June 30, 2017
N=48,943

Health plan enrollment was not
continuous six months before
and after diagnosis
N=20,602

Continuous health plan enrollment six
months before and after diagnosis
N=28,341

Under the age of 18
N=37
Age > 18
N=28,304

No biopsy procedure
identified
N=5,434

Study Population
At least one biopsy procedure
identified
N=22,870

Multiple biopsy procedures of
different types
N=7,303
Focused Study Population
N=15,567

Figure 1 Lung cancer patient characteristics by biopsy status.

the complication was from the biopsy or a surgical
treatment.

Cost Analysis
Total costs associated with a lung cancer diagnosis from
the combined payer and patient perspectives beginning 6
months prior to index date through treatment date were
included in the analyses. Costs of chest CT scans, biopsy,
and post-biopsy complications were estimated from total
payments, as reported in the claims data. Costs for ser
vices provided under capitated arrangements were esti
mated using payment proxies that were computed based
on average paid claims at the procedure level in the
claims data. Costs of biopsy included both procedure
and physician payment in the outpatient setting. Biopsy
performed in the inpatient setting included all costs

ClinicoEconomics and Outcomes Research 2021:13

incurred to the payer during the entire hospital stay,
including complication costs. Costs were normalized to
2017 US dollars using the US Bureau of Labor
Statistics’ Consumer Price Index Medical Care
Component.
Costs associated with outpatient biopsies and inpatient
biopsies where the biopsy occurs within the first 2 days of
hospitalization are simply the reported payments. Biopsies
that occur on the third day or later in a hospitalization are
counted in this analysis, but the cost associated with the
biopsy requires careful treatment. Attributing the entire
payment for a hospitalization with what might be consid
ered to be an incidental biopsy would overstate the true
cost of the biopsy. Likewise, omitting any payment would
understate the true cost. As a compromise, the costs of
inpatient biopsies that occur after day 3 are estimated by
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the average cost of the same type of biopsy occurring in an
outpatient setting.
All analyses were conducted using the statistical soft
ware SAS, version 9.4 (SAS Institute Inc.).

Results
A total of 73,732 patients with a primary diagnosis and
evidence of treatment for lung cancer in their records
between January 1, 2013 and December 31, 2017 were
identified in the IBM MarketScan® database (Figure 1). Of
these, 24,789 patients were diagnosed before July 1, 2013
or after June 30, 2017 and were excluded from further
analyses. An additional, 20,502 did not have evidence of
continuous health insurance enrollment. Only 37 patients
were ineligible due to age limits, leaving a total of 28,304
patients for the final analytical sample. The study popula
tion includes 81% of patients (N=22,870) with evidence of
one or more biopsies in their claims data. Those patients
with no evidence of biopsy (19.2%) tended to be younger
than the overall population average, have higher Charlson
comorbidity scores, have a history of cancer (both with
and without evidence of metastasis), have no evidence of
CT scans, and a greater percentage with the period from
diagnosis to treatment exceeding 6 months (Table 1).
Fifty-eight percent of patients (N=13,270) underwent
only one biopsy procedure of which 48.3% were percuta
neous, 41.2% were bronchoscopic, 9.4% were surgical and
1.1% were mediastinoscopy (Table 2). Another 27.7%
required two, and the remaining 14.2% required three or
more biopsy procedures. For the 41.9% of patients with
more than one biopsy procedure of the same type, the
overall percentage and distribution of procedures remained
similar with slight increases in the frequency of surgical
and mediastinoscopy procedures. Viewing these data by
the type of procedure shows that 33.8% of patients had
one or more percutaneous biopsies, 28.0% had one or
more bronchoscopic biopsies, 5.5% had one or more sur
gical biopsies and less than 1% had one or more medias
tinoscopies. Approximately 32% had multiple biopsies of
different types. (Supplemental Information)
In order to assess complication rates by biopsy type,
we examined only patients receiving one or more biopsy
procedures of the same type, resulting in a focused study
population of 15,567 patients. Complication rates were
highest among those patients receiving percutaneous
biopsy, followed by bronchoscopy, mediastinoscopy and
surgery (Table 3). Infection among patients undergoing
surgical biopsy or mediastinoscopy was relatively rare.
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There were no cases of infection among those undergoing
percutaneous or bronchoscopic biopsy procedures.
Median cost (and interquartile range) of single and multi
ple biopsies, occurring in outpatient or inpatient settings, or
both for some multiple biopsies are presented in Table 4.
Median costs, including the biopsy, CT scan, and complica
tions, were highest for inpatient surgical biopsies ($29,988)
and lowest for outpatient percutaneous biopsies ($1028).
Repeat biopsy procedures of the same type were most com
mon in patients who had a percutaneous or bronchoscopic
biopsy. Repeat biopsies of the same type increased costs by
40–80%. The mean costs, irrespective of biopsy type, were
$11,350, $23,651, $29,800, and $42,520 for one, two, three,
or four or more biopsy procedures, respectively.
Median total costs varied substantially by setting. Over
one-quarter (29%) of all biopsies were performed as inpa
tient diagnostic procedures. Inpatient biopsies were cost
lier than outpatient biopsies by a factor of 8 (single
mediastinoscopy) to 20 (single surgical). Inpatient biopsies
accounted for 81% of total costs.
Rates of complications varied substantially by type of
procedures, though only a fraction of complications required
further interventions that resulted in additional costs.
Incremental costs associated with complications averaged
$667, which corresponds to 13% of total costs. Complication
costs were 11% of costs of patients receiving only one biopsy
and 20% for patients receiving 2 or more biopsies.

Discussion
Nearly 42% of the study population underwent two or more
biopsy procedures prior to the initiation of treatment, adding as
much as 40–80% to the per patient median cost for percuta
neous and bronchoscopic procedures. Bronchoscopic and per
cutaneous biopsies accounted for approximately 90% of the
procedures while surgery accounted for 10%, which is similar
to the 11.4% reported by Vyas in 2013.9 Using the same
Marketscan® database, Zhang et al analyzed the frequency of
biopsy procedures in a lung cancer patient population for
2013–15,10 and Shinde et al analyzed the frequency of biopsy
procedures in a lung cancer patient population using erlotinib
or crizotinib for 2009–2012.11 Zhang et al used the same
continuous enrollment criteria of 6 months prior to and 6
months following biopsy and did not examine costs. Shinde
et al selected patients based on an index claim for the use of
either erlotinib or crizotinib, and continuous enrollment 12
months prior to and 12 months following biopsy. Even with
these differences, our findings in terms of the number of
additional procedures are quite similar to both studies.
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Table 1 Lung Cancer Patient Characteristics by Biopsy Status
Variable

No Biopsy
N

Total

%

n

Received Biopsies
%

n

P value

%

28,304

100.0

5434

19.2

22,870

80.8

18–44

866

3.1

226

4.2

640

2.8

45–54
55–64

3442
10,234

12.2
36.2

845
2016

15.6
37.1

2597
8218

11.4
35.9

65–74

7375

26.1

1291

23.8

6084

26.6

75–84
85+

5287
1100

18.7
3.9

828
228

15.2
4.2

4459
872

19.5
3.8

13,750

48.6

2553

47.0

11,197

49.0

14,554

51.4

2881

53.0

11,673

51.0

EPO

225

0.8

39

0.7

186

0.8

HMO
POS

2573
1836

9.1
6.5

521
354

9.6
6.5

2052
1482

9.0
6.5

14,386

50.8

2816

51.8

11,570

50.6

9284

32.8

1704

31.4

7580

33.1

5518

19.5

1146

21.1

4372

19.1

2014

8444

29.8

1680

30.9

6764

29.6

2015
2016

6568
5430

23.2
19.2

1209
1003

22.3
18.5

5359
4427

23.4
19.4

2017

2344

8.3

396

7.3

1948

8.5

6056

21.4

1033

19.0

5023

22.0

6629
15,619

23.4
55.2

817
3584

15.0
66.0

5812
12,035

25.4
52.6

20,597

72.8

3105

57.1

17,492

76.5

5883

20.8

1594

29.3

4289

18.8

998
826

3.5
2.9

475
260

8.7
4.8

523
566

2.3
2.5

6878

24.3

2047

37.7

4831

21.1

18,442

65.2

2903

53.4

15,539

67.9

2615
369

9.2
1.3

402
82

7.4
1.5

2213
287

9.7
1.3

2531

8.9

608

11.2

1923

8.4

23,811

84.1

4160

76.6

19,651

85.9

1962

6.9

666

12.3

1296

5.7

Age at diagnosis

Gender
Male
Female

<0.001

<0.01

Type of insurance

PPO
Other
Year of diagnosis
2013

0.0945

<0.001

Charlson comorbidities index*
0
1
2+
Cancer history*
No
Yes (No metastatic record)
Yes (Metastasis to other organs)
Yes (Metastasis to lung)
Total CT scans*
0
1
2
3+
Time from diagnosis to treatment
Same day
Within 6 months
More than 6 months

<0.001

<0.001

<0.001

<0.001

Notes: Others include comprehensive, Medicare wrap-around, consumer driven, and high deductible health plans, and missing values. Asterisk*Clinical characteristics were
identified up to 6 months prior to lung cancer diagnosis.
Abbreviations: Type of insurance: EPO, exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider
organization.
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Table 2 Distribution of Biopsies by Frequency
Patients
Biopsy Procedures

Percutaneous

Bronchoscopy

Surgical

Mediastinoscopy

n

%

n

%

n

%

n

%

n

%

1 procedure

13,270

58.0

6410

48.3

5468

41.2

1244

9.4

148

1.1

2 procedures
3 procedures

6342
2266

27.7
9.9

5124
2641

40.4
38.9

5264
2629

41.5
38.7

1601
798

12.6
11.7

695
730

5.5
10.7

992
22,870

4.3
100.0

1834
16,009

41.6
43.1

1636
14,997

37.1
40.4

429
4072

9.7
11.0

509
2082

11.6
5.6

≥ 4 procedures
Overall

Note: Average procedures per patient: 1.6 (37,160 biopsies divided by 22,870 patients).

Complication rates following biopsy procedures likely
depend upon a variety of factors including patient char
acteristics (eg, comorbidities, location of lesions), proce
dural processes (eg, puncture time length), the length of
time following the procedure to assess a complication and
the type of study (eg, case series vs clinical trial). In the
recent literature, pneumothorax with transthoracic needle
aspiration remains the most frequently reported complica
tion, with rates ranging from 15% to 25%, of which
6–11% of those patients requiring a chest tube for
management.12,13 A recent meta-analysis by Heerink
et al reported a pooled pneumothorax complication rate
of 25.3% and 18.8% for a core biopsy and fine-needle
aspiration, respectively. However, pneumothorax compli
cation rates varied widely from 8.4% to 53.5%. The
pooled estimate for bleeding complications was 18% and
6.4% for a core biopsy and fine-needle aspiration, respec
tively. Bleeding complication rates showed even more
variability ranging from 2.9% to 54.4%.14 In our study,
the complication rates for pneumothorax and hemorrhage
following percutaneous biopsy were 14.64% and 2.2%,
respectively. One possible explanation for the lower rates
observed in our study is the exclusion of 7303 patients
who received multiple biopsy procedures of different
approaches. The inclusion of this subset into complication
rate estimates is a subject for further study.
To ensure that we accurately achieve the objective of
our study to evaluate the total costs, we included specific
procedure codes and limited the window of observation to
ensure that our study complication rates were similar to
other published findings; thus validating complication
rates and ensuring that interventions to patient clinical
pathways which would impact costs. As such, the compli
cation rate associated with bronchoscopic procedures is
considerably lower than the complication rate associated
with percutaneous procedures. In a meta-analysis of
guided bronchoscopy for the evaluation of the pulmonary
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nodule, Memoli et al reported a pneumothorax rate of
approximately 1.5% and no events of bleeding.15 In
a multi-center study of consecutive patients undergoing
bronchoscopy, rates of pneumothorax and hemorrhage
were 1.7% and 0.1%, respectively.16 Our results show
comparable findings for pneumothorax but higher rates
for hemorrhage or bleeding given the varying degree of
hemorrhage and the subsequent need for blood
transfusion.17 While our study finds a higher rate of
hemorrhage, we also find that these patients did not require
an intervention of transfusion; indicating that these bleed
types were of minor complexity and resolved on their own.
Furthermore, published complication rates for surgical
biopsy are approximately 5%, inclusive of air leaks and
pneumonia.3 In our study, approximately 2% of patients
undergoing surgical biopsy experienced air leaks and
pneumonia, lower, but comparable to previously published
findings.
Lung cancer has been estimated to cost approximately
$60,000 in the first year after diagnosis and approximately
$8000 per year thereafter. Costs during the last year of life
may exceed $90,000.18,19 There is little information on the
costs of lung cancer from nodule biopsy to cancer therapy. In
this study, repeat biopsies increased costs by 40–80%.
Lokhandwala and colleagues estimated the total diagnostic
cost for patients from an abnormal chest CT scan to assess
ment for lung cancer diagnosis using Medicare data and
reported a combined value of $38.3 million in their final
sample, of which 43.1% was accounted for by patients
receiving biopsy procedures without lung cancer.20
Huo et al estimated complication costs following
biopsy procedures and reported mean incremental costs
of $6320 for minor complications to $56,845 for major
complications.21 However, their analysis included costs
for complications for one full year, rather than an episo
dic analysis of 1 day to 5 days post procedure, and also
included surgical treatment within the surgical biopsy

ClinicoEconomics and Outcomes Research 2021:13
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Notes: Asterisk*: excluding CPT 32507 and CPT 32668. Complication diagnosis was identified by ICD-9-CM or ICD-10-CM diagnosis codes.

25.00

–
–
0
–
0.32
1.20
–
–
Empyema
Abscess of lung

–
–

–
–

–
–

0
0

0

2.40
1.75

33.33
0.24

–
–
–

–

–

Pneumonia

–

–

–

0

10.00
5.99
2.79
3.63
2.09

mechanical ventilation
Mediastinitis

Change in clinical status to intubated/

12.5
0
0.31
2.20
Prolonged air leak
Hemorrhage

2.47

3.01

0

0
0
1.99
3.35
2.94
0
0.53
8.20

0
0

2.40
3.59

0
4.79
dwelling catheter

Pneumothorax with or without in

14.64

5.83

–
3.66
2.56

–

Requiring
Intervention
Complications
Requiring
Intervention
Complications
Requiring
Intervention
Complications
Requiring
Intervention
Complications
Complication

Surgical* (n = 1254)
Bronchoscopy (n = 6413)
Percutaneous (n = 7733)

Table 3 Post-Procedural Complications in Patients Who Received at Least One Biopsy and Patients Requiring Clinical Intervention (Unit: %)

Mediastinoscopy (n = 167)

Chiu et al

definition. Our finding of average complication costs was
$667, 13% of the overall median costs, suggesting lower
cost associated with complications. Multiple biopsies
create additional costs due to the procedure itself, as
well as additional costs associated with complications
associated with the second, third or fourth biopsy. We
attribute all of the costs of complications to the compli
cation directly. A case could be made for attributing
some of the costs of complications to having multiple
biopsies, making the 13% value an overestimate.
Our analysis suggests that the key drivers of the costs
of biopsies are repeat procedures and the procedure set
ting. The lower impact of complication costs in this study
may also be attributable to the exclusion of patients with
multiple biopsy types, though some portion of complica
tion costs may be attributable to the process of multiple
biopsies. Additionally, patients were only counted once for
the rates of different types of complication even though
there may have been multiple reports of the same type of
complication. Complications were rarely associated with
treatment, identified by a unique procedure code within the
timing conditions of this study. The impact of episodic
MS-DRG bundling on the costs of complications is
unknown.

Limitations
As with any data source, IBM MarketScan® has limita
tions. Claims data come mostly from large employers
providing coverage for their employees and dependents.
The study population does not include persons who are
uninsured, publically insured other than by Medicare, or
persons without continuous enrollment. Unique to the US,
nearly 30% of those diagnosed with lung cancer in these
data did not have evidence of continuous health insurance
enrollment, which is typically associated with a person’s
changing employment status or employer’s changing
insurance. The study likely disproportionately excludes
persons who have low incomes. Thus, the results may
not be generalizable to the US population as a whole,
nor to other jurisdictions where the entire population is
insured.
Claims data are focused on administrative rather than
clinical information. Clinical information that may be very
relevant in analyses of complications and costs, such as the
stage of disease upon diagnosis, are not included in claims
data. For this discussion of lung cancer, the absence of
additional clinical information is an important limitation.
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Table 4 Median Cost of Biopsy Procedure and Interquartile Range (IQR) by Type, Number of Procedures and Care Setting, Inclusive
of Complications Cost
Procedures/
Location
1 Procedure

Percutaneous

Surgical

Bronchoscopy

Mediastinoscopy

(n = 7733)

(n = 1254)

(n = 6413)

(n = 167)

n=5321

n=87

n=4130

n=92

$1028.52
[1543.01]

$1487.64
[3202.58]

$2577.14
[3636.34]

$3740.24
[6407.14]

n=1089*
$9058.13

n=1157
$29,988.03

n=1338*
$15,758.46

n=56*
$26,026.82

[18,134.05]

[26,655.81]

[29,427.67]

[35,015.81]

2+ Procedures
Outpatient

n=874
$1704.73
[2681.40]

–

n=534
$4083.74
[6162.69]

n=18
$6639.89
[9252.49]

2+ Procedures
Both Outpatient

n=311*
$12,914.44

n=3
$26,497.98

n=339*
$29,891.68

–

and Inpatient

[17,761.92]

[25,317.69]

[33,608.41]

Outpatient

1 Procedure
Inpatient

2+ Procedures

n=138*

n=7

n=72*

n=1

Inpatient

$18,475.94
[26,969.22]

$48,332.88
[39,080.67]

$35,994.37
[51,440.86]

$16,806.26
[n/a]

Notes: Asterisk*: selected inpatient and combination. Both outpatient and inpatient include biopsies that occurred outside of the range of hospital day −1 to +2, where
costs were estimated to be the median cost of outpatient biopsies of the same type.

A large number of patients, 5434 (19.2%), were
observed to have lung cancer therapy with no evidence
of biopsy. Zhang et al found an even higher percentage of
patients (45.7%) with a lack of identifiable biopsy within 6
months of diagnosis.10 Some patients, with a history of
cancer or a first observed diagnosis on claims beyond 6
months, may have merely experienced delayed treatment.
However, it is a mystery how the diagnosis of cancer was
made for these patients and reflects a limitation of the data.
We can provide no estimate of the costs of a lung cancer
diagnosis for these patients. Further, using a 6-month time
period may have limited observing some costs associated
with a protracted diagnosis process.
We used a single diagnosis of lung cancer in the
primary diagnosis position as evidence of lung cancer.
By using only claims data, we did not have a confirmed
pathological diagnosis of cancer. A single diagnosis may
not be a severe limitation. Ramsey et al evaluated the
sensitivity of a single medical claim with a lung cancer
diagnosis, which was confirmed with the SEER registry,
and reported a sensitivity of 99.4% for commercial plan
members.22
Claims were counted until the point of treatment.
While we attempted to separate diagnosis and treatment
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claims, we may have included some costs associated with
treatments if claims for diagnosis and treatments were
combined. This is particularly a concern for patients with
inpatient admissions. The costs presented for inpatient
biopsies may be biased upwards from true costs.
This analysis also excluded patients who received mul
tiple biopsy types, a population subset that may have more
complications, limiting the scope of the analysis. With
multiple biopsy types, we were unable to attribute costs
and complications to a specific biopsy. We also limited the
inclusion of complications to those occurring within a time
window of 1 day to 3 days after the procedure. Analysis of
complication rates and costs associated with multiple
biopsy types in this population, longer time windows for
observing complications, as well as analyses of the asso
ciations among patients’ demographic characteristics,
complications and costs, are subjects for further research.

Conclusion
Healthcare costs associated with the diagnosis of lung cancer
are primarily driven by repeat procedures and setting (inpa
tient versus outpatient). In our analysis, 41.9% of diagnosed
and treated lung cancer patients undergo multiple biopsies,
increasing mean healthcare costs by 40–80% depending on
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procedure type. Multiple biopsies add substantially to the cost
burden of lung cancer diagnosis, leaving an opportunity for
technological advancements that increase accuracy and effec
tiveness, leading to fewer repeat biopsies. Over one-quarter of
procedures were performed on an inpatient basis, leaving an
opportunity for greater use of outpatient services, when medi
cally appropriate, to substantially reduce payer costs.
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